A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa-Reference-Cited by-同舟云学术

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

Published:2020-04 Issue: Volume:21 Page:100313
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Bekker Linda-Gail,Dintwe One,Fiore-Gartland Andrew,Middelkoop Keren,Hutter Julia,Williams Anthony,Randhawa April K.,Ruhwald Morten,Kromann Ingrid,Andersen Peter L.,DiazGranados Carlos A.,Rutkowski Kathryn T.,Tait Dereck,Miner Maurine D.,Andersen-Nissen Erica,De Rosa Stephen C.,Seaton Kelly E.,Tomaras Georgia D.,McElrath M. Juliana,Ginsberg Ann,Kublin James G.^ORCID

Funder

National Institute of Allergy and Infectious Diseases

U.S. Public Health Service

NIH

NIAID Duke Center for AIDS Research

Bill & Melinda Gates Foundation

United Kingdom Department for International Development

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.